Interestingly, some studies suggest that Fibroblast Growth Factor 4 may have a protective effect against nonalcoholic steatohepatitis (NAS) by suppressing the cleavage and activation of CASP6 via the AMP-activated protein kinase (AMPK) signaling pathway [36]. Here, FGF4 is linked to metabolic dysfunction-associated steatohepatitis.